SARS-CoV-2 Vaccination May Have Reduced Effectiveness in Patients with Multiple Melanoma

While SARS-CoV-2 vaccination has been proven safe and effective in the general population, patients with multiple myeloma (MM) were not included in vaccination trials, so data regarding vaccine effectiveness in this patient population is not known.

This multicenter retrospective cohort study in the Veterans Affairs (VA) healthcare system followed vaccinated and unvaccinated patients with MM and a matched less immunocompromised comparison population.

Vaccine effectiveness in the matched cohort of patients with MM was 22.2% starting 14 days after the second dose and in the matched cohort of cancer survivors it was 82.3%. Additionally, 8.7 per 1000 patients in the MM matched cohort were infected with SARS-CoV-2 following vaccination, compared to 4 per 1000 in the matched cohort of cancer survivors.